New Drug Approvals

Home » COMPANIES » Founder of leading Indian pharmaceutical company, Sun Pharmaceuticals has been named India’s third richest man

Founder of leading Indian pharmaceutical company, Sun Pharmaceuticals has been named India’s third richest man

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Recent Posts

Blog Stats

  • 3,662,584 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,650 other followers

add to any

Share

dilip

This is the first time Mr Dilip Shanghvi, founder of Sun Pharmaceutical has been named in the top three with a 66 percent surge in his wealth –

25 oct 2013

Singapore: For the first time, founder of leading Indian drugmaker Sun Pharmaceuticals, Mr Dilip Shanghvi has been named in the top three of India’s richest men. Mr Shanghvi has made an appearance in the list prepared by China based ‘Hurun India Rich List’ as the third richest Indian man with a 66 percent surge in his wealth. Energy tycoon and Reliance Industries chairman Mr Mukesh Ambani has topped the list as India’s richest man with personal assets of $18.9 billion, news reports mentioned. The report pointed out that Mr Ambani has retained the top position for the second year even after a wealth decrease of two percent. London-based steel baron Mr Lakshmi Narayan Mittal has been named the second richest, with assets of $15.9 billion. – See more at: http://www.biospectrumasia.com/biospectrum/news/199210/sun-pharma-s-founder-named-india-s-3rd-richest#.Umzu4fmnqls

Read more at: http://www.biospectrumasia.com/biospectrum/news/199210/sun-pharma-s-founder-named-india-s-3rd-richest#.Umzu4fmnql
s

Potential of US pipeline continues to be under appreciated

SUNP’s US pipeline is shaping up well, with an interesting mix of complex products, branded generics and me-too products. Motilal Oswal believe that SUNP’s strong pipeline in the US is well placed to deliver revenue CAGR of 25% to USD1.8b. While a meaningful contribution to this growth is being led by Doxil and recently acquired URL Pharma, we estimate that SUNP’s own pipeline is set to witness revenue CAGR of 40% to USD6 20m. They build flat sales growth for Taro as they expect incremental competition to impact the market share for key Taro products. If competition is delayed, their estimates may have room for positive surprise.

Even after a 50-plus per cent return in one year, Sun Pharma’s stock continues to hold promise. While domestic revenues are growing well, US sales growth has been phenomenal, driven by a strong product pipeline and the acquisitions of Taro, DUSA, URL generics and Caraco.

  1. [PDF]

    NCE & NDDS Development Pipeline – Sun Pharma

    www.sunpharma.com/pressdownload.php?download_file=329.pdf

    NCE & NDDS Development Pipeline / 2. Disclaimer. Except for the historical information contained herein, statements in this presentation and the subsequent 

  2. [PDF]

    Pipeline of Potential Ocular Therapies to Help Millions  – Sun Pharma

    www.sunpharma.com/pressdownload.php?…Press%20Release%20SunPh

    Oct 1, 2013 – 1. For Immediate Release. Sun Pharma and Intrexon Form Joint Venture to Develop. New Class of Therapeutics for Ocular Diseases. Pipeline 

    pipeline

    Sun Pharma Advanced Research (SPARC, US$345
    mn market cap), a proprietary product research
    company, detailed its NDDS and NCE product pipelines
    in its latest filing with the SEBI, pursuant to its proposed
    rights issue. Overall, there has been modest
    clinical/regulatory progression in the NDDS pipeline
    since the last disclosure six-seven months back. See
    Exhibits 1 and 4 inside.
    Key highlights: Big picture – New Drug Delivery
    System (NDDS) – Overall SPARC is developing a
    diverse collection of seven technology platforms for oral,
    injectable and topical delivery systems (including nano
    particulate, bio-degradable depot, DPI, SMM, GFR).
    SPARC has 19 NDDS products under development.
    New Chemical Entity (NCE) – The company has a
    pipeline of five compounds that are pro-drugs of existing
    molecules (such as baclofen, gabapentin etc). The NCE
    pipeline appears to be in its early stages, with market
    launch a few years away.
    Update on key products (NDDS) – Three lead drugs:
    1) levetiracetam XR 1000/1500 mg (505(b)(2) filing with
    USFDA is now targeted for F1Q13), 2) baclofen GRS
    (Special Protocol Assessment, SPA, agreement has
    been received from FDA and patient enrollment for
    Phase 3 studies is targeted in F4Q12) and 3) BAK-free
    latanoprost (Phase III patient enrollment over in US).
    These timelines imply that the first product launch in the
    US is likely in 2H13. SPARC continues to validate its
    underlying technology platforms by launching drugs in
    the domestic market (six proprietary launches, seven
    generic launches so far).
    Other milestones for CY12: IND filing with USFDA for
    two drugs – Octreotide Depot Inj (1 month) and Dry
    Powder Inhaler (Salmeterol and Fluticasone
    combination); paclitaxel (with carboplatin) Phase I
    results in US and clinical progress of second WRAP
    based drug, cardiovascular agent (and its combination)

    NDDS

    LATANOPROST

    LATANOPROST+TIMOLOLOL

    BACLOFEN VENLAFAXINE

    LEVETIRACETAM

    PICN, PACLITAXEL

    NCE

    SUN597,

    SUN L731

    SUN K706

    OTHERS

    DRY POWDER INHALER

    DOCETAXEL NANODISPERSION

    OCTEOTIDE

    MAY 2013
    mn market cap), a proprietary product research
    company, detailed its NDDS and NCE product pipelines
    in its latest filing with the SEBI, pursuant to its proposed
    rights issue. Overall, there has been modest
    clinical/regulatory progression in the NDDS pipeline
    since the last disclosure six-seven months back. See
    Exhibits 1 and 4 inside.
    Key highlights: Big picture – New Drug Delivery
    System (NDDS) – Overall SPARC is developing a
    diverse collection of seven technology platforms for oral,
    injectable and topical delivery systems (including nano
    particulate, bio-degradable depot, DPI, SMM, GFR).
    SPARC has 19 NDDS products under development.
    New Chemical Entity (NCE) – The company has a
    pipeline of five compounds that are pro-drugs of existing
    molecules (such as baclofen, gabapentin etc). The NCE
    pipeline appears to be in its early stages, with market
    launch a few years away.
    Update on key products (NDDS) – Three lead drugs:
    1) levetiracetam XR 1000/1500 mg (505(b)(2) filing with
    USFDA is now targeted for F1Q13), 2) baclofen GRS
    (Special Protocol Assessment, SPA, agreement has
    been received from FDA and patient enrollment for
    Phase 3 studies is targeted in F4Q12) and 3) BAK-free
    latanoprost (Phase III patient enrollment over in US).
    These timelines imply that the first product launch in the
    US is likely in 2H13. SPARC continues to validate its
    underlying technology platforms by launching drugs in
    the domestic market (six proprietary launches, seven
    generic launches so far).
    Other milestones for CY12: IND filing with USFDA for
    two drugs – Octreotide Depot Inj (1 month) and Dry
    Powder Inhaler (Salmeterol and Fluticasone
    combination); paclitaxel (with carboplatin) Phase I
    results in US and clinical progress of second WRAP
    based drug, cardiovascular agent (and its combination)

     

     


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,650 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: